Combined anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies are associated with increased Sjögren's disease severity through interferon pathway activation.
Eléonore BettacchioliAlain SarauxAlice TisonDivi CornecMaryvonne DueymesNathan FoulquierSophie HillionAnne-Marie Roguedas-ContiosAnas-Alexis Benyoussefnull nullnull nullMarta E Alarcon-RiquelmeJacques-Olivier PersValérie Devauchelle-PensecPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
These results suggest that the combination of anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies is associated with a clinical, biological, and transcriptional profile linked to greater disease severity in SjD, through the potentiation of the interferon pathway activation by anti-Ro52/TRIM21 antibodies.